Why Did Aurora Cannabis (TSX:ACB) Stock Jump 16% After Curaleaf Raised Its Hostile Takeover Offer by 25%?

Aurora Cannabis Inc. (TSX:ACB) (NASDAQ:ACB) shares rose about 16% in Monday morning trading in New York and Toronto after Curaleaf Holdings Inc. (OTCQX:CURLF) raised its unsolicited takeover offer by 25% to $5 a share, escalating a campaign that Aurora’s board has so far declined to engage with.

The improved proposal, announced October 5, would give Aurora shareholders 0.4013 Curaleaf subordinate voting shares plus $1 in cash for each Aurora share. The original August bid, which Aurora’s board rejected unanimously, was 0.3463 shares plus $0.75 in cash. It was worth about $4 a share and valued Aurora at roughly $272 million at the time. Curaleaf shares were essentially flat at C$14.18 in Toronto.

What Curaleaf Changed

The cash component rises 33% and now makes up about 20% of the consideration, so most of the offer remains tied to Curaleaf’s stock. Curaleaf also raised the cap price, the maximum consideration per Aurora share, by 20% to $6. It calls that level a 118% premium to Aurora’s unaffected share price.

Curaleaf said the new terms represent an 86% premium to that unaffected price, defined as Aurora’s 30-day volume-weighted average price of $2.75 as of August 10, the day before the bid was announced. The company also agreed to include the pro forma financial statements Aurora had requested and extended the offer’s expiry to December 4.

Jordan Presses Aurora’s Board to Talk

Curaleaf Chairman and Chief Executive Officer Boris Jordan said the company sweetened the offer even though Aurora has refused to engage or provide customary due diligence, the review of a target’s financial and legal records. He said the enhanced proposal was built solely from public information and urged Aurora’s board to enter good-faith discussions.

Shareholders deserve a fair and open process, Jordan said, if other parties are being given access to Aurora’s information. He added that Curaleaf has met with a significant share of Aurora’s investor base in recent weeks and that all of them backed the strategic rationale for a combination. In earlier comments, he described the higher price as a way to draw out rival suitors and pressure management to negotiate.

The Case for a Combined Company

Curaleaf argues that a merged business would operate in 17 countries and generate more than $1.5 billion in trailing 12-month revenue and nearly $350 million in adjusted EBITDA, or earnings before interest, taxes, depreciation and amortization. It also projects at least $40 million in annual cost synergies and a pro forma market capitalization above $3 billion.

Curaleaf further says the combined company would have a lower cost of capital than Aurora has today. These figures are Curaleaf’s own projections, drawn from public information, and have not been verified by Aurora.

What the Rally Signals

Aurora’s double-digit gain suggests investors now see a higher chance that the bid succeeds, is improved again, or draws a competing offer. That reading is an inference from the price move, not a statement from either company.

Market data indicated Aurora later closed up 14.2% at C$6.37, a smaller gain than the morning peak but still a sharp advance for a stock that had been under pressure.

For Aurora shareholders, the structure carries trade-offs. Because roughly 80% of the consideration is paid in Curaleaf shares, the value of the offer will move with Curaleaf’s stock price, while the $6 cap limits the upside if that price rises. Holders who want certainty may prefer a larger cash component, a point Aurora’s board could raise if talks begin.

What to Watch Next

The board’s response is the key variable. A hostile bid depends on shareholders accepting the terms before the December 4 expiry, and Aurora has not agreed to the proposal or opened its books. Investors should watch for any formal reply from the board, further changes to the terms, and the emergence of other bidders.

Curaleaf’s decision to raise its offer, extend the deadline and supply the financial statements Aurora requested shows it is willing to keep pressing. Whether that persistence turns into a negotiated deal or a prolonged standoff will determine if Monday’s jump holds.

This article is for informational purposes only and is not investment advice. Investors should consult a licensed adviser before making decisions.